05.01.13
Strahlman |
“I am very pleased that Dr. Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus,” said Forlenza. “She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries, and her patient-centric approach aligns with our focus on providing innovative solutions to address the healthcare needs of customers and patients.”
Strahlman joins BD from pharmaceutical giant GlaxoSmithKline (GSK), where she served as senior vice president and CMO since 2008 and more recently worked in the office of the CEO as senior medical advisor and global head of neglected tropical diseases. As GSK’s CMO, Strahlman had accountability for safety and patient matters for all programs in development and commercialized products in the vaccines, pharmaceutical and consumer businesses, as well as organizational responsibility for medical affairs, regulatory affairs, clinical safety and other areas. Prior to GSK, Strahlman held executive leadership roles at Merck & Co., Novartis Corporation, Pfizer Inc., and Bausch & Lomb that included oversight of the development and commercialization of proprietary and generic pharmaceuticals, drug delivery systems and medical devices.
Strahlman obtained her medical degree from the Johns Hopkins University School of Medicine in Baltimore, Md., her M.H.Sc. from the Johns Hopkins School of Public Health, and her B.A. from Harvard University in Cambridge, Mass.
BD is medical technology company that develops medical devices, instrument systems and reagents.